Milltrust International has launched the British Innovation Fund II and Milltrust Ventures, which aims to target high-impact, early-stage companies with links to UK University science and innovation. The fund focuses on supporting start-ups with cutting-edge intellectual property capable of disrupting various industries. The British Innovation Fund II has already invested in three thematic verticals of Green Earth, Smart Proteins, and Future Health. Milltrust Ventures has a strong track record of identifying winning companies, including Roslin Technologies, Vaccitech, and Oxford Science Enterprises. The firm operates in a regulated capacity across multiple jurisdictions, including the UK, Singapore, Ireland, and Cayman, and has a client base that includes pension funds, sovereign entities, family offices, entrepreneurs, and HNWIs.
Milltrust Launches British Innovation Fund II and Milltrust Ventures for High-Impact Start-Ups
Milltrust International, an award-winning investment organization focused on ‘Sustainable Prosperity,’ is launching the British Innovation Fund II and a dedicated venture investment platform, Milltrust Ventures. The fund aims to target high-impact, early-stage companies with connections to UK University science and innovation.
The British Innovation Fund II aims to support promising start-ups with cutting-edge intellectual property capable of disrupting various industries. Milltrust has deep connections with leading British research institutions, universities, and NGOs, which leverages British Innovation Fund II further in supporting start-ups.
The British Innovation Fund II has already invested across three thematic verticals of Green Earth, Smart Proteins, and Future Health, supporting UK science and innovation. The fund is particularly focused on global food systems and health, identified as key post-pandemic priorities for both the UK and the world.
To strengthen the team, Milltrust Ventures has appointed Dr Bernard Ng as Chief Scientific Officer, who is a medical and clinical affairs leader and former Chief Medical Officer at Bayer consumer division. Moreover, Hadyn Craig has been appointed to the board of Milltrust Ventures and brings unique expertise in agriculture and food-systems from previous roles as CEO of Capital Agri International and as a senior consultant at AbacusBio Limited. Finally, Harry Paul joins as venture partner, bringing 30 years of experience in medical tech and agri-investment, including a former role in Milltrust’s successful farmland investments, sold to LPPI in 2022.
Milltrust International Launches Milltrust Ventures with a Strong Track Record
Milltrust International, an award-winning investment organization co-headquartered in London and Singapore, has launched Milltrust Ventures with a strong track record of 69 prior and 16 new fund investments. Milltrust has a strong track record of identifying winning companies, including cutting-edge biotech company Roslin Technologies, Oxford Science Enterprises, and vaccine developer Vaccitech.
Other investments include Attomarker, a unique blood testing diagnostic platform revolutionising personalised medicine, and Polymateria, a technology developed at Imperial College. The successful exit from BIF I has enabled Milltrust Ventures to reinvest at an advantageous time, with valuation metrics more appealing for investors today.
Simon Hopkins, CEO, Milltrust International, said, “The creation of Milltrust Ventures represents a significant step forward in our strategy to foster Sustainable Prosperity across the globe, recognising the outsized positive impact that rapidly-growing, IP-rich companies can have and the unique alpha they can provide to investors.”
Clients include pension funds, sovereign entities, family offices, entrepreneurs, and HNWIs. The firm operates in a regulated capacity across multiple jurisdictions, including the UK, Singapore, Ireland, and Cayman.
For more information, contact Simon Hopkins, CEO Milltrust International Group at info@milltrust.com.
Don’t miss interesting posts on Famousbio
